Patents by Inventor Gabriel Ortega

Gabriel Ortega has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11946098
    Abstract: Electrochemical sensors have great promise for point-of-care and in vivo measurement of medically relevant molecules. However, the need for calibrating individual sensors limits the practical applicability of these sensing platforms. The invention provides a novel method of operating electrochemical sensors which obviates the need to calibrate individual sensors against a sample of known concentration. The invention exploits the frequency dependence of electrochemical output signals and the dependence of output signals on the inherent electron transfer kinetics of a selected sensor design. By use of signals generated at a nonresponsive frequency, a normalizing output value is generated that accounts for sensor-to-sensor variation and which enables an accurate calculation of target concentration. The scope of the invention also includes pre-calibrated sensors that may be utilized without calibration steps.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: April 2, 2024
    Assignee: The Regents of the University of California
    Inventors: Kevin Plaxco, Hui Li, Philip Dauphin-Ducharme, Gabriel Ortega
  • Publication number: 20230273211
    Abstract: A method of diagnosing breast cancer is disclosed. The method comprises lysing extracellular vesicles of a subject to generate a composition comprising components of extracellular vesicles; measuring the amount of MEK1 in the composition; and diagnosing the subject with breast cancer when a level of said MEK1 in said composition is above a predetermined threshold. Kits for breast cancer diagnosis are also disclosed.
    Type: Application
    Filed: March 30, 2023
    Publication date: August 31, 2023
    Applicants: Yeda Research and Development Co. Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Sima LEV, Yaron VINIK, Francisco Gabriel ORTEGA, Mordechai GUTMAN MD
  • Publication number: 20200182820
    Abstract: Electrochemical sensors have great promise for point-of-care and in vivo measurement of medically relevant molecules. However, the need for calibrating individual sensors limits the practical applicability of these sensing platforms. The invention provides a novel method of operating electrochemical sensors which obviates the need to calibrate individual sensors against a sample of known concentration. The invention exploits the frequency dependence of electrochemical output signals and the dependence of output signals on the inherent electron transfer kinetics of a selected sensor design. By use of signals generated at a nonresponsive frequency, a normalizing output value is generated that accounts for sensor-to-sensor variation and which enables an accurate calculation of target concentration. The scope of the invention also includes pre-calibrated sensors that may be utilized without calibration steps.
    Type: Application
    Filed: June 1, 2018
    Publication date: June 11, 2020
    Applicant: The Regents of the University of California
    Inventors: Kevin Plaxco, Hui Li, Philip Dauphin-Ducharme, Gabriel Ortega
  • Publication number: 20170321261
    Abstract: The present invention provides an in vitro method of detecting circulating tumour cells, circulating tumour cells of epithelial phenotype and circulating tumour cells of epithelial to mesenchymal transition (EMTs), in a biological sample using, as an indicator, expression levels of miRNA-21, and obtaining a result of the method by comparing the expression levels of said miRNA-21 with a negative control or with a positive control, wherein if the expression levels in the cells of the biological sample are over-expressed in comparison to a negative control is indicative of the presence of circulating tumour cells in said biological sample or wherein if the expression levels in the cells of the biological sample are expressed in an amount greater than ? of the maximum expression achieved in a positive control is indicative of the presence of circulating tumour cells in said biological sample.
    Type: Application
    Filed: September 18, 2015
    Publication date: November 9, 2017
    Inventors: María José SERRANO FERNÁNDEZ, Juan José DÍAZ MOCHÓN, Francisco GABRIEL ORTEGA, José Antonio LORENTE ACOSTA, José Luis GARCÍA PUCHE, Maria Paz RUIZ BLAS, Rosario María SÁNCHEZ MARTÍN
  • Publication number: 20160273047
    Abstract: The inventors of the present invention have surprisingly discovered that EGFR expression in nonmetastatic breast cancer patients with CK-negative CTCs could induce EMT process. A simultaneous detection of both EGFR and EMT markers (VIM and Slug) in CTCs might improve prognostic or predictive information in patients with operable breast cancer.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 22, 2016
    Inventors: José Luis GARCÍA PUCHE, María José SERRANO FERNÁNDEZ, José Antonio LORENTE ACOSTA, Juan Antonio MARCHAL CORRALES, Francisco Gabriel ORTEGA SÁNCHEZ
  • Patent number: D849371
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: May 28, 2019
    Assignee: Brooks Sports, Inc.
    Inventor: Gabriel Ortega
  • Patent number: D849372
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: May 28, 2019
    Assignee: Brooks Sports, Inc.
    Inventor: Gabriel Ortega